Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.10 | -0.16 | 0.07 |
| FCF Yield | -17.28% | -76.73% | -118.30% | -35.07% |
| EV / EBITDA | -2.27 | -0.20 | -0.09 | -0.04 |
| Quality | ||||
| ROIC | -34.44% | -140.78% | -64.00% | -43.78% |
| Gross Margin | 97.66% | 94.67% | 92.72% | 92.88% |
| Cash Conversion Ratio | 0.94 | 0.66 | 1.45 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.57% | -7.77% | -3.36% | – |
| Free Cash Flow Growth | 9.20% | 37.08% | -61.29% | 28.34% |
| Safety | ||||
| Net Debt / EBITDA | 2.26 | 0.64 | 1.07 | 1.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,276.42 | -622.75 | -1,391.27 | -2,305.02 |